Related Experiment Video
Updated: Mar 20, 2026
Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies
Published on: November 5, 2016
Regenerative Medicine Strategies for Hypoplastic Left Heart Syndrome
Josue Chery1, Joshua Wong2, Shan Huang1
11 Department of Cardiac Surgery, University of Michigan , Ann Arbor, Michigan.
Insights
Hypoplastic left heart syndrome (HLHS) leads to right ventricle (RV) failure in adults. Regenerative medicine offers potential new treatments for this severe congenital heart defect.
Area of Science:
- Cardiology
- Regenerative Medicine
- Congenital Heart Defects
Background:
- Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect affecting left heart structures.
- HLHS survivors face significant long-term morbidities, including right ventricle (RV) failure.
- RV failure in HLHS differs from acquired heart disease, presenting unique challenges.
Purpose of the Study:
- To explore the potential of regenerative medicine in treating RV failure in HLHS patients.
- To highlight the need for novel therapeutic strategies for HLHS long-term survivors.
Main Methods:
- Review of current understanding of RV failure in HLHS.
- Discussion of regenerative medicine approaches like stem cell therapy and cardiac tissue engineering.
- Exploration of mechanisms such as angiogenesis and oxidative stress mitigation.
Main Results:
- The single right ventricle (RV) is vulnerable to chronic pressure overload, leading to early failure in HLHS patients.
- Regenerative medicine strategies show promise in preserving or improving RV function.
- New functional myocardium creation is a potential therapeutic goal.
Conclusions:
- Regenerative medicine, including stem cell therapy and cardiac tissue engineering, holds revolutionary potential for HLHS treatment.
- Significant hurdles remain before clinical translation of these advanced therapies.
- Novel treatments are crucial for HLHS patients with limited long-term options.
Abstract:
Hypoplastic left heart syndrome (HLHS), the most severe and common form of single ventricle congenital heart lesions, is characterized by hypoplasia of the mitral valve, left ventricle (LV), and all LV outflow structures. While advances in surgical technique and medical management have allowed survival into adulthood, HLHS patients have severe morbidities, decreased quality of life, and a shortened lifespan. The single right ventricle (RV) is especially prone to early failure because of its vulnerability to chronic pressure overload, a mode of failure distinct from ischemic cardiomyopathy encountered in acquired heart disease. As these patients enter early adulthood, an emerging epidemic of RV failure has become evident. Regenerative medicine strategies may help preserve or boost RV function in children and adults with HLHS by promoting angiogenesis and mitigating oxidative stress. Rescuing a RV in decompensated failure may also require the creation of new, functional myocardium. Although considerable hurdles remain before their clinical translation, stem cell therapy and cardiac tissue engineering possess revolutionary potential in the treatment of pediatric and adult patients with HLHS who currently have very limited long-term treatment options.
More Related Videos
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:29Cardiomyopathy V: Interprofessional Care